Sunshine Biopharma, Inc.

121 articles about Sunshine Biopharma, Inc.

• Management Of Sunshine Biopharma, Inc. Alarmed By The Recent World Health Organization Report That Cancer Is On The Rise

  4/1/2014

• Sunshine Biopharma, Inc. Begins Construction Of Mouse Xenograft Models For Pancreatic Cancer To Advance Adva-27a As A Treatment For This Deadly Form Of Cancer

  2/17/2014

• Sunshine Biopharma, Inc. Continues Its Efforts To Re-Domicile In Canada For Business Expansion And Financing Opportunities For Adva-27a Cancer Drug Candidate

  2/5/2014

• Sunshine Biopharma, Inc. Targets Pancreatic Cancer As Second Indication For Clinical Trials Of Adva-27a Compound

  1/21/2014

• Sunshine Biopharma, Inc. Parent Company Acquires Garmen Laboratories, a Certified GMP Manufacturing Lab

  8/26/2013

• Sunshine Biopharma, Inc. Parent Company Receives $510,000 Research Grant for Adva-27a Cancer Drug Candidate, Brings Total to $1.45 Million

  8/12/2013

• Sunshine Biopharma, Inc.: Court Ruling on Human Genes Patentability Didn't Affect Tasks

  6/19/2013

• Sunshine Biopharma, Inc. Announces That Its Breast Cancer Drug Candidate, Adva-27a, Also Destroys Pancreatic Cancer Cells

  6/4/2013

• Sunshine Biopharma, Inc. Narrows Kilogram Manufacturing Options for Adva-27a Breast Cancer Drug Candidate to Three Suppliers

  5/1/2013

• Sunshine Biopharma, Inc. HMEC Study Indicates Novel Anticancer Compound Adva-27a Non-Toxic at High Concentrations

  4/9/2013

• Sunshine Biopharma, Inc. Commences Negotiations With Contract Manufacturing Organizations for Production of Its Multidrug-Resistant Breast Cancer Drug, Adva-27a

  3/14/2013

• Sunshine Biopharma, Inc. Reports on IND Research for Its Novel Breast Cancer Drug Candidate, Adva-27a

  2/26/2013

• Advanomics Corporation, the Parent Company of Sunshine Biopharma, Inc., Files a New Patent Application for Its Multidrug Resistance Adva-27a Anticancer Compound

  1/15/2013

• Sunshine Biopharma, Inc. Completes Another IND-Enabling Study: Adva-27a is Found to be Effective Against Multidrug Resistant Uterine Cancer Cells

  12/10/2012

• Sunshine Biopharma, Inc. Completes Six IND-Enabling Studies for Its Anticancer Compound, Adva-27a

  12/4/2012

• Advanomics Corporation, the Parent Company of Sunshine Biopharma, Inc., Completes Acquisition of Adva-27a Patents

  11/27/2012

• Sunshine Biopharma, Inc. Receives Scale-Up Manufacturing Protocol for Its Lead Anti-Cancer Compound, Adva-27a

  10/9/2012

• Sunshine Biopharma, Inc.'s Adva-27a Preclinical Research Results to be Published in October Issue of Anticancer Research

  9/25/2012

• Sunshine Biopharma, Inc. Advances to Next Phase of Drug Development With Lead Anti-Cancer Compound, Adva-27a

  9/13/2012

• Sunshine Biopharma, Inc. Takes Delivery of Newly Manufactured Batch of Adva-27a and Proceeds to Conducting Biological Verification of the Compound's Anti-Cancer Activity

  9/4/2012